CARE Ratings Limited (CARERATING)
₹1,603.90 +2.42% last close, 16 Oct
Q2 FY27 results
📅 Next results: 29 Oct 2026 (board meeting)CARE Ratings Limited's board meets on 29 Oct 2026 to consider its Q2 FY27 results (July-September 2026).
In its latest reported quarter, Q1 FY27, CARE Ratings' revenue was ₹112 Cr (+18.8% year on year, -14.7% on the previous quarter), and net profit ₹33.0 Cr (+26.9% year on year); the operating margin was 31.0%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹112 | +18.8% | -14.7% |
| Operating profit | ₹34.6 | +23.7% | -43.2% |
| Net profit | ₹33.0 | +26.9% | -37.7% |
| EPS (₹) | 10.73 | +24.6% | -39.0% |
| Operating margin | 31.0% | — | — |
CARERATING delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 56.22% of the CARERATING shares traded on NSE were taken to delivery, against the stock's own 20-session average of 62.65%. That is close to its usual level. Volume was 0.5 times its average, well below normal.
Delivery in the last 5 sessions: 59.2% · 59.8% · 68.0% · 55.4% · 56.2%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
CARE Ratings has announced upcoming in-person meetings with institutional investors scheduled for September 21, 2026. The company is set to meet Quest Investment Managers at 2:30 PM and Bandhan Mutual Fund at 4:30 PM. The discussions will center strictly on publicly available information using an already published investor presentation. As a routine investor relations update, this filing does not present any direct financial impact on the company's ₹491 crore TTM revenue base.
- Meeting with Quest Investment Managers scheduled for September 21, 2026 at 2:30 PM
- Meeting with Bandhan Mutual Fund scheduled for September 21, 2026 at 4:30 PM
- Both interactions will be conducted as in-person meetings
- Discussions will rely strictly on publicly available information and existing presentations
CARE Ratings Limited has informed the exchanges of a scheduled virtual meeting with TenCore Partners on September 9, 2026, at 8:00 PM. The company noted that discussions will strictly adhere to publicly available information and investor presentations already filed. With a market capitalization of ₹5,258 Cr and TTM revenue of ₹491 Cr, such regular institutional interactions are part of routine investor relations.
- Meeting scheduled with institutional investor TenCore Partners
- Date and time of meeting: September 9, 2026, at 8:00 PM
- Format: Virtual meeting
- Discussions to be based strictly on publicly available information
CARE Ratings Limited has informed the exchanges regarding the cancellation of its Analyst/Institutional Investor meeting scheduled for September 3, 2026, at 8:00 PM IST. The meeting was originally intimated via an exchange letter dated August 20, 2026. The company cited unforeseen exigencies as the reason for the cancellation. This is a purely administrative disclosure under Regulation 30 with no material operational or financial impact.
- Cancellation of investor/analyst meeting scheduled for September 3, 2026, at 8:00 PM IST
- Reference to prior meeting intimation letter dated August 20, 2026
- Cancellation attributed to unforeseen exigencies under Regulation 30 of SEBI LODR
CARE Ratings Limited has approved the allotment of 24,500 equity shares of face value Rs. 10 each following the exercise of stock options under the CARE Employee Stock Option Scheme 2020. Consequently, the company's paid-up share capital increases from Rs. 30,09,39,120 (3,00,93,912 shares) to Rs. 30,11,84,120 (3,01,18,412 shares). The equity dilution resulting from this allotment is marginal at approximately 0.08%.
- Allotment of 24,500 equity shares approved pursuant to ESOP Scheme 2020
- Paid-up share capital rises to Rs. 30,11,84,120 from Rs. 30,09,39,120
- Total share count increases to 3,01,18,412 shares of Rs. 10 face value
- Equity dilution from the allotment is minimal at ~0.08%
CARE Ratings Limited has informed the stock exchanges that it will conduct an in-person meeting with SteadFort Investment Managers on September 10, 2026, at 12:30 PM. The discussions will be strictly based on publicly available information and the existing investor presentation. This is a routine institutional interaction notification pursuant to SEBI Listing Regulations.
- Institutional investor meeting scheduled with SteadFort Investment Managers
- Meeting date set for 10th September 2026 at 12:30 PM
- Format of the interaction is in-person
- Discussions will adhere strictly to publicly available information
CARE Ratings Limited has announced a scheduled in-person meeting with institutional investor Artisan Partners on September 10, 2026, at 2:30 PM. The company noted that discussions will strictly be based on publicly available information and existing investor presentations. As a standard regulatory intimation under SEBI LODR Regulation 30, this disclosure has no direct operational or financial impact on the company.
- Meeting scheduled with institutional investor Artisan Partners
- Date and time of meeting: 10th September 2026 at 02:30 PM
- Meeting format: In-person interaction
- Discussions to remain restricted to publicly available company information
CARE Ratings Limited has informed the exchanges regarding a timing change for its scheduled interaction with Oyster Rock Capital. The meeting, originally slated for Wednesday, 26th August 2026 at 3:15 PM IST, has been moved to 5:15 PM IST on the same day due to exigencies. The company confirmed that discussions will rely solely on publicly available information and no unpublished price-sensitive information will be shared.
- Meeting with Oyster Rock Capital rescheduled on 26th August 2026
- Time updated from 3:15 PM IST to 5:15 PM IST on 26th August 2026
- No unpublished price sensitive information (UPSI) will be discussed
CARE Ratings Limited has announced a scheduled institutional investor meeting with TenCore Partners on September 3, 2026, at 08:00 PM IST via virtual mode. The company confirmed that discussions will be restricted to publicly available information, referring to its latest investor presentation. This filing is a standard procedural compliance under Regulation 30 of SEBI (LODR) Regulations, 2015.
- Scheduled virtual investor meeting with TenCore Partners on September 3, 2026
- Meeting set for 08:00 PM IST via virtual conferencing
- Discussions confirmed to be restricted strictly to publicly available information
CARE Ratings Limited has announced the schedule for institutional investor interactions from August 24 to August 26, 2026. The company is set to meet four institutional entities: 12 Flags (virtual), Bandhan Mutual Fund (in person), Pari Washington (in person), and Oyster Rock Capital (in person). Management stated that discussions will strictly be based on publicly available information.
- Virtual meeting scheduled with 12 Flags on 24th August 2026 at 02:30 PM
- In-person meeting with Bandhan Mutual Fund on 25th August 2026 at 11:00 AM
- Two in-person meetings on 26th August 2026: Pari Washington at 02:00 PM and Oyster Rock Capital at 03:15 PM
- Discussions will rely exclusively on publicly available information
CARE Ratings Limited has announced an in-person meeting scheduled with Marcellus Investment Managers on 19th August 2026 at 04:00 PM. The company noted that discussions will be based solely on publicly available information, and its investor presentation is accessible via its website. For a company with a market cap of Rs 5,225 Cr and TTM revenue of Rs 491 Cr, this represents a standard institutional investor relations disclosure.
- One-on-one institutional investor meeting scheduled with Marcellus Investment Managers
- Meeting date fixed for 19th August 2026 at 04:00 PM IST
- Mode of meeting confirmed as In Person
- Discussions to be strictly based on publicly available information
CARE Ratings Limited has announced a scheduled in-person meeting with Hill Fort Capital on August 27, 2026. This meeting is part of the company's regular investor engagement following a fiscal year (FY26) where revenue grew to ₹473 crore with a healthy 41.6% operating margin. The discussions will be restricted to publicly available information, ensuring no selective disclosure of material data. With a market capitalization of ₹5,231 crore, such institutional interactions are standard practice for maintaining transparency.
- In-person meeting scheduled with Hill Fort Capital on August 27, 2026, at 2:00 PM
- Company reported TTM revenue of ₹473 crore and PAT of ₹173 crore as of the latest cycle
- Non-rating segments (Analytics, Consulting, Sustainability) now contribute 11% to total revenue
- Operating profit margins remained robust at 41.6% for the TTM period
CARE Ratings Limited has scheduled an analyst and institutional investor meeting for August 12, 2026, in Mumbai. The event, 'EMKAY Confluence 2026', will involve discussions based on publicly available information. This follows a fiscal year (FY26) where the company reported a revenue of ₹473 Cr and a PAT of ₹173 Cr. Such meetings are standard practice for maintaining institutional relations and do not typically involve the disclosure of unpublished price-sensitive information.
- Investor meet scheduled for August 12, 2026, starting at 10:00 AM
- Event organized by Emkay Global Financial Services in Mumbai
- Company reported TTM revenue of ₹473 Cr and TTM PAT of ₹173 Cr
- Non-rating segments (Analytics, Consulting, Sustainability) currently contribute 11% to total revenue
CARE Ratings reported a consolidated operating income of ₹111.68 Cr for Q1 FY27, marking an 18.9% YoY increase. Consolidated PAT grew by 24.6% to ₹32.99 Cr, reflecting improved operational efficiency with an EBITDA margin of 31.0%. Despite a 29.3% decline in overall corporate bond issuances in the economy, the company's core ratings business grew 19.1% YoY, supported by strong bank credit growth of 18.6%. The non-ratings segment, including analytics and ESG, contributed ₹12.97 Cr to the top line.
- Consolidated Operating Income grew 18.9% YoY to ₹111.68 Cr in Q1 FY27.
- Consolidated PAT increased by 24.6% YoY to ₹32.99 Cr, with a PAT margin of 26.1%.
- Ratings business revenue rose 19.1% YoY to ₹98.71 Cr despite a sharp 29.3% drop in market-wide corporate bond issuances.
- Non-ratings business revenue grew 17.9% YoY to ₹12.97 Cr, now a key diversification pillar.
- CARE ESG Ratings maintained a dominant 58% market share in the Category 1 ERP (Issuer Pay's Model) segment.
CARE Ratings reported a strong start to FY27 with consolidated operating income growing 18.9% YoY to ₹111.68 Cr. Despite a 29.3% decline in the broader corporate bond market, the company's ratings business grew 19.1% YoY, supported by robust bank credit growth of 18.6%. Profitability improved significantly, with consolidated PAT rising 24.6% to ₹32.99 Cr and EBITDA margins reaching 31.0%. The non-ratings segment, including analytics and ESG, contributed ₹12.97 Cr, maintaining its growth trajectory.
- Consolidated Operating Income grew 18.9% YoY to ₹111.68 Cr in Q1 FY27
- Consolidated PAT increased by 24.6% YoY to ₹32.99 Cr
- Ratings business revenue rose 19.1% YoY to ₹98.71 Cr despite a 29.3% drop in corporate bond issuances
- Non-ratings business (Analytics, ESG, Consulting) contributed ₹12.97 Cr, up 17.9% YoY
- Bank credit growth accelerated to 18.6% YoY, providing a strong tailwind for the ratings business
CARE Ratings reported a steady Q1 FY27 with standalone revenue from operations growing 16.5% YoY to ₹88.15 Cr. Standalone Net Profit increased by 16.3% YoY to ₹33.88 Cr, despite a significant 42.9% rise in other expenses. The company's international subsidiaries contributed ₹8.61 Cr to the consolidated revenue. EPS for the quarter improved to ₹11.27 from ₹9.72 in the previous year's corresponding quarter.
- Standalone Revenue from operations grew 16.5% YoY to ₹88.15 Cr from ₹75.64 Cr.
- Standalone Net Profit rose 16.3% YoY to ₹33.88 Cr compared to ₹29.12 Cr in Q1 FY26.
- Other expenses increased significantly by 42.9% YoY to ₹12.54 Cr.
- International subsidiaries (3 units) contributed ₹8.61 Cr to total consolidated revenue.
- The company allotted 13,400 equity shares during the quarter under its ESOP 2020 scheme.
Financial Performance
Revenue Growth by Segment
Ratings business revenue grew 16% YoY to Rs. 205.75 Cr in H1 FY26, while the non-ratings segment recorded a strong 30% YoY growth to Rs. 24.53 Cr. For FY2025, consolidated revenue from operations reached Rs. 402.32 Cr, a 21.30% increase from Rs. 331.68 Cr in FY2024.
Geographic Revenue Split
Primarily India-focused, though the company is expanding its global footprint through 'CareEdge Global' with strategic MOUs in regions like Mauritius. Specific percentage splits by region are not disclosed in available documents.
Profitability Margins
Consolidated PAT margin stood at 33% in H1 FY26 (Rs. 83.71 Cr), while Standalone PAT margin was 39% (Rs. 84.95 Cr). For FY2025, consolidated PAT margin was 34.8% (Rs. 140.01 Cr), up from 30.9% in FY2024.
EBITDA Margin
Consolidated EBITDA margin was 42% in H1 FY26 (Rs. 96.30 Cr), up 24% YoY. Standalone EBITDA margin reached 57% in Q2 FY26 (Rs. 64.97 Cr), reflecting high operational efficiency in core rating services.
Capital Expenditure
Net Block of assets stood at Rs. 119.21 Cr as of March 31, 2025, representing a 10% increase from Rs. 108.82 Cr in FY2024, driven by investments in technology and infrastructure.
Credit Rating & Borrowing
Not disclosed as the company appears to be debt-free; Debt-Equity and Interest Coverage ratios are listed as Not Applicable (NA) in standalone financial summaries.
Operational Drivers
Raw Materials
As a service-based agency, the primary 'raw material' is human capital; employee costs represent 46.9% of total revenue (Rs. 188.92 Cr in FY2025).
Key Suppliers
Not applicable; the business relies on professional analysts and technological infrastructure rather than physical raw material suppliers.
Capacity Expansion
Not applicable in MT/MW; however, the company is expanding its 'rating universe' and geographical reach, resulting in an increase in new rating market share by count in FY2025.
Raw Material Costs
Employee costs, the primary operational expense, grew 14.79% YoY to Rs. 188.92 Cr in FY2025, reflecting investments in talent retention and skill upgrading.
Manufacturing Efficiency
Manufacturing efficiency is not applicable; however, debtors turnover ratio was 12.54x in FY2025, and the company is upgrading ML models to improve data extraction efficiency.
Strategic Growth
Expected Growth Rate
17-21%
Growth Strategy
Growth will be achieved by diversifying into non-rating segments (Analytics, Consulting, Sustainability) which now contribute 11% to revenue, and by capitalising on new SEBI mandates such as monitoring equity issuance proceeds. The company is also expanding globally via CareEdge Global and focusing on high-growth sectors like Infrastructure and BFSI.
Products & Services
Credit ratings for corporate bonds, commercial papers, and bank loans; Integrated Credit Platform (ICP) for risk analytics; ESG and sustainability assessments; Monitoring of equity issuance proceeds.
Brand Portfolio
CareEdge, CareEdge Ratings, CareEdge Global, CareEdge Analytics, CareEdge Advisory.
New Products/Services
Monitoring of equity issuance proceeds (market leader) and Past Risk and Return Verification Agency services (SEBI approved).
Market Expansion
Expanding into the International Financial Services Centre (GIFT City) and global markets like Mauritius.
Market Share & Ranking
Leading credit rating agency in India with a leadership position in Infrastructure and BFSI segments; securitisation volumes grew 55% in FY2025.
Strategic Alliances
Strategic MOUs with entities like the Mauritius Chamber of Commerce and Industry to drive global growth.
External Factors
Industry Trends
The industry is evolving toward integrated risk solutions and data analytics. Regulatory shifts, such as SEBI's 'Ease of doing business' initiatives and cyber security frameworks, are redefining operational standards.
Competitive Landscape
Operates in a regulated oligopoly; maintains leadership in Infrastructure and BFSI while facing competition from other domestic rating agencies.
Competitive Moat
Moat is sustained by mandatory regulatory requirements (SEBI/RBI accreditation) and high switching costs due to reputation. CareEdge's leadership in Infrastructure and high stability ratios provide a durable competitive advantage.
Macro Economic Sensitivity
Highly sensitive to GDP growth and private investment cycles; muted private investment in FY2025 impacted the core rating business growth momentum.
Consumer Behavior
Corporates are increasingly using commercial papers (issuances up 18.5% in H1 FY26) as a flexible funding tool compared to long-term bonds during yield volatility.
Geopolitical Risks
Global economic volatility and US reciprocal tariffs are identified as external headwinds that could impact domestic demand and corporate fundraising.
Regulatory & Governance
Industry Regulations
Regulated by SEBI (CRA Regulations) and RBI (Basel-III framework). New mandates include monitoring equity issuance proceeds and adhering to the SEBI 'Cyber security and resilience framework' (2025).
Environmental Compliance
Not disclosed; service industry has low direct environmental impact.
Taxation Policy Impact
Effective tax rate of 27.1% in FY2025, with total tax expenses of Rs. 52.26 Cr on a PBT of Rs. 192.27 Cr.
Risk Analysis
Key Uncertainties
Potential implementation of the Internal Rating Based (IRB) approach by RBI could make external ratings non-mandatory for some banks, impacting 89% of the company's revenue stream.
Geographic Concentration Risk
Revenue is primarily concentrated in India (approx. 100% of current segments), though global expansion is underway.
Third Party Dependencies
Primary dependency is on human capital and regulatory licenses from SEBI and RBI.
Technology Obsolescence Risk
Mitigated by upgrading ML models and implementing a robust IT security policy to protect data integrity and maintain analytical superiority.
Credit & Counterparty Risk
Trade receivables stood at Rs. 32.09 Cr in FY2025, with a healthy debtors turnover ratio of 12.54x.